---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-041486"
form_type: "8-K"
ticker: null
cik: "0001840574"
company_name: "Verve Therapeutics, Inc."
filed_at: "2023-02-17T23:59:59+00:00"
generated_at: "2026-06-19T08:17:31.052148+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Verve Therapeutics amends bylaws to align with universal proxy rules

## Summary
- Board approved Second Amended and Restated Bylaws effective February 14, 2023.
- Eliminates requirement to provide stockholder list during meetings; adds adjournment for technical failures.
- Enhances nomination procedures: requires disclosure and 67% voting power solicitation under Rule 14a-19.
- Non-compliant nominations will be disregarded; proxies or votes for such nominees not counted.
- Includes technical, conforming, and clarifying changes.

## SEC filing metadata
- accession: 0001193125-23-041486
- form_type: 8-K
- cik: 0001840574
- company_name: Verve Therapeutics, Inc.
- filed_at: 2023-02-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840574/000119312523041486/0001193125-23-041486-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840574/000119312523041486/d447068d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-041486
- JSON: https://secwatch.observer/filing/0001193125-23-041486.json
- Plain text: https://secwatch.observer/filing/0001193125-23-041486.txt

## Key facts
- Governance Changes
  Verve Therapeutics, Inc.: Amendment and restatement of bylaws eliminating stockholder list requirement during meetings, addressing remote meeting adjournment due to technical failure, and revising procedural mechanics for stockholder nominations and proposals under universal proxy rules (effective 2023-02-14).
  - Change: bylaw amendment
  - Effective: 2023-02-14
  source text: On February 14, 2023, the board of directors (the “Board”) of Verve Therapeutics, Inc. (the “Company”) approved an amendment and restatement of the Company’s Amended and Restated Bylaws (as so amended and restated, the “Second Amended and Restated Bylaws”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840574/000119312523041486/0001193125-23-041486-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.